Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

ClinicalTrials.gov ID: NCT01493778

Public ClinicalTrials.gov record NCT01493778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A

Study identification

NCT ID
NCT01493778
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
60 participants

Conditions and interventions

Interventions

  • turoctocog alfa Drug

Drug

Eligibility (public fields only)

Age range
0 Years to 6 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 16, 2012
Primary completion
Aug 15, 2017
Completion
Dec 4, 2018
Last update posted
Nov 29, 2020

2012 – 2018

United States locations

U.S. sites
25
U.S. states
17
U.S. cities
23
Facility City State ZIP Site status
Novo Nordisk Investigational Site Phoenix Arizona 85016-7710
Novo Nordisk Investigational Site Long Beach California 90806
Novo Nordisk Investigational Site Sacramento California 95817
Novo Nordisk Investigational Site Washington D.C. District of Columbia 20010-2978
Novo Nordisk Investigational Site Gainesville Florida 32610
Novo Nordisk Investigational Site Orlando Florida 32827
Novo Nordisk Investigational Site Tampa Florida 33606
Novo Nordisk Investigational Site Tampa Florida 33607
Novo Nordisk Investigational Site Augusta Georgia 30912
Novo Nordisk Investigational Site Macon Georgia 31201
Novo Nordisk Investigational Site Savannah Georgia 31404
Novo Nordisk Investigational Site Oak Lawn Illinois 60453
Novo Nordisk Investigational Site Detroit Michigan 48201
Novo Nordisk Investigational Site Las Vegas Nevada 89109
Novo Nordisk Investigational Site New Brunswick New Jersey 08901
Novo Nordisk Investigational Site Brooklyn New York 11201-5425
Novo Nordisk Investigational Site Brooklyn New York 11220
Novo Nordisk Investigational Site Charlotte North Carolina 28204
Novo Nordisk Investigational Site Cincinnati Ohio 45229
Novo Nordisk Investigational Site Dayton Ohio 45404
Novo Nordisk Investigational Site Oklahoma City Oklahoma 73104
Novo Nordisk Investigational Site Portland Oregon 97239
Novo Nordisk Investigational Site Charleston South Carolina 29425
Novo Nordisk Investigational Site Salt Lake City Utah 84113
Novo Nordisk Investigational Site Charlottesville Virginia 22908

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01493778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 29, 2020 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01493778 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →